Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123588 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03123588 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 12 participants.
The verdict
NCT03123588, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Interventions
- DRUG Placebo
- DRUG Ruxolitinib
- DRUG Anagrelide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2020-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03123588
The ClinicalTrials.gov registry entry for NCT03123588 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03123588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03123588 about?
NCT03123588 is a clinical study titled "Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
What is the current status of trial NCT03123588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-11-14. Estimated completion is 2020-08-03.
What interventions are being tested in trial NCT03123588?
The interventions under investigation include: Placebo (DRUG), Ruxolitinib (DRUG), Anagrelide (DRUG).
Who is sponsoring clinical trial NCT03123588?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.